Short-acting intramuscular olanzapine for acute agitation: clinical and cost - effectiveness and guidelines
CADTH
Record ID 32014000753
English
Authors' recommendations:
Three non-randomized studies were identified regarding the clinical effectiveness of short-acting intramuscular olanzapine for the treatment of acute agitation associated with bipolar disorder or schizophrenia; no evidence-based guidelines were identified.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/may-2014/RB0671%20IM%20Olanzapine%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Injections, Intramuscular
- Benzodiazepines
- Antipsychotic Agents
- Bipolar Disorder
- Schizophrenia
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.